Crinetics (CRNX) Reports First Quarter 2026 Earnings and Business Update
Crinetics Pharmaceuticals reported Q1 2026 earnings with $10.7 million in total revenue, driven by Palsonify sales of $10.3 million. The company noted growth in new patient enrollments and an increase in treatment-naive patients using its drug.
Tickers: $CRNX
Topics: market_expansion patient_enrollments pharmaceuticals revenue